



Current Status and Future Plans for Experiment AD-4
Biological Effectiveness of Antiproton Annihilation
Michael Holzscheiter1, Jan Alsner2, Angelo Angelopoulos3, Niels Bassler2,4, Gerd Beyer5, John DeMarco6,
Michael Doser7, Dragan Hajdukovic8, Oliver Hartley5, Adam Hunniford9, Kei Iwamoto6, Oliver Jäkel4,
Ioannis Kantemiris3, Helge Knudsen10, Sandra Kovacevic8, Bill McBride6, Søren Pape Møller10, Robert
McCullough9, Jens Overgaard2, Jørgen Petersen2, Osman Ratib5, Timothy Solberg11, Ulrik Uggerhøj10,
Sanja Vranjes12, and Brad Wouters13
1 University of New Mexico
2Aarhus University Hospital
3 University of Athens
4 Deutsches Krebsforschungszentrum
5 Geneva University Hospital
6 University of California at Los Angeles
7 CERN
8 University of Montenegro
9 Queens University of Belfast
10 Aarhus University
11 University of Nebraska Medical Center
12 Vinca Institute of Nuclear Sciences
13University of Maastricht
Summary
A first round of experiments conducted in 2003 and 2004 at CERN and at TRIUMF have shown a
significant enhancement of the biological effective dose ratio (BEDR) for antiprotons compared
to protons. The experimental methods and analysis as well as the definition of terms used are
described in the 2006 publication in Radiotherapy & Oncology (see appendix A). In 2006 the
AD-4 collaboration conducted a set of experiments at higher beam energy and therefore deeper
penetration into the target. This allowed for the first time the use of a clinically relevant spread-
out Bragg peak (SOBP). Early 2007 we performed a set of irradiations using the same methods
and materials at GSI with carbon ions giving the same penetration depth and the same SOBP as
the antiprotons at CERN. Due to problems with the a priori estimate of dose in the case of
antiprotons, a number of data points were rendered. During the 2008 AD-4 Run in week 42 this
problem was rectified and a large set of biological data were taken. The remaining missing link to
presenting these results in publishable form is a control measurement using a standard Cobalt
radiation source and the exact cell lines and preparation routines used in October.
Parallel to the biological measurements with antiprotons in 2007 and 2008 we performed
detailed dosimetric studies of the antiproton beam. Using Alanine tablets and ionization chambers
to measure the response to the antiproton beam and comparing these results to predictions using
different Monte Carlo calculations, we were able to benchmark the FLUKA code package.
As a result of the work in 2007 and 2008 we submitted three papers of which two are
accepted and in press (see Appendices B and C). The third paper (on absolute dosimetry using
Alanine tablets) is in the final review stage with the referees and we expect acceptance in the very
near future.
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 II. Introduction:
The overall goal of the AD-4 Experiment is to study the biological effect of
antiprotons in order to validate earlier theoretical predictions that antiprotons could
produce a yield a better therapeutic ratio for the treatment of well defined tumors. This
prediction is based on two observations:
1. The physical dose should be augmented near the end of range due to the
additional energy deposited locally when antiprotons annihilate.
2. Some of the additional energy deposited results from low energy heavy ion recoils
produced in the annihilation event, which are expected to exhibit a higher
biological efficiency.
For this purpose several studies are needed. One is a detailed measurement of the
dose deposition of an antiproton beam of a specific energy entering a biological target,
which then can be compared to Monte Carlo calculations and can be used to benchmark
different available codes. The second piece of information needed is the relative
biological effect with respect to a standard radiation type (typically a 60Co source) along
the path of the antiproton beam, preferably for a number of different cell lines extensively
used in cancer therapy. Once these two questions are answered one can then use these
results as input data for treatment planning tools and develop comparative treatment plans
for a specific tumor for antiprotons, carbon ions, and protons. Based on these plans we
would then be able to determine specific incidences of cancer where antiprotons could
provide a significant benefit to patients.
Since antiproton annihilation also yields a significant component of medium and
high-energy secondary particles, which will leave the annihilation vertex, a third, very
critical, issue to be studied is the biological effect of this background on cells outside the
direct target area.
 III. Biological Measurements:
In October 2006 we performed our first studies of cell survival using a 502 MeV/c
antiproton beam from the AD. This beam energy allowed a penetration into our target of
approximately 10 cm and much more closely resembled possible therapeutic situations.
In addition we used a set of passive degraders to generate a spread-out Bragg peak of 10
mm depth, irradiating a volume of approximately 300 mm3. A typical dose-depth profile
for both antiprotons is shown in figure 1.
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Fig. 1: Typical relative depth dose profile used at CERN for antiprotons obtained from FLUKA.
In 2006 we performed 4 different irradiations with nominal dose values of 0.25, 0.5,
1, and 5 Gy. Due to high uncertainties in estimating the absolute dose only the lowest
three dose values yielded useful data, which were presented in the last report (SPSC-
2007-020/M-756). For the 2007 run period we had improved our dosimetry capabilities
and were able to control the absolute dose delivered to the target to within 10%, allowing
us to augment above data sets. We performed irradiations on V79 cells for 6 different
dose values. These dose values were selected using FLUKA based on dosimetric
information obtained before the irradiation. Control measurements between different
badges were performed to assure the stability of the beam delivery system. The raw data
obtained are shown in figure 2 below.
Fig. 2: Survival fraction vs. depth in the target for V79 Chinese Hamster cells irradiated with
antiprotons. The dose values for the individual runs were estimated from FLUKA calculations
using the number of antiprotons delivered and the radial beam profile obtained from radiochromic
film irradiated simultaneously with the cell samples and analyzed after the run. The dose values
were A: 2.3 Gy; B: 1.6 Gy; D: 0.5 Gy; E: 6.0 Gy; F: 0.8 Gy; Z: 9.0 Gy.
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The above results need to be compared to an experiment using carbon ions conducted
in early 2007 at GSI. Here a beam of clinical quality and absolute dosimetry was
available and irradiations of 8 samples with plateau dose values between 0.3 and 4.0 Gy
were performed. Survival data vs. depth are shown in figure 3.
Figure 3: Survival fraction vs. depth in the target for V79 Chinese Hamster cells irradiated with
carbon ions
The cell kill in the plateau region is noticeable higher for carbon ions than for
antiprotons at similar plateau dose. This is due to the elevated RBE of carbon ions
already in the entrance channel. Also noticeable is the earlier and more gradual increase
of cell kill for carbon ions compared to antiprotons.
Figure 4 shows the results of our analysis for the carbon ion experiment. Defining the
plateau as data points 1 and 2 and the peak as points 9 – 14 of the depth survival curve we
can plot survival vs. absolute dose for peak and plateau. In addition we plot survival vs.
dose for a reference X-ray source with low LET and RBE of 1. Using a survival rate of
10% we extract the RBE0.1 for carbon ions as 1.38 in the plateau and 2.17 in the peak.
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Figure 4: Survival fraction vs. absolute for V79 Chinese Hamster cells irradiated with carbon ions.
By comparing the dose needed to achieve a survival of 10% using low LET X-rays to the dose
needed when using carbon ions we extract a relative biological efficiency of 1.38 in the plateau
and 2.17 in the peak.
In order to perform the same analysis for antiprotons we are currently still lacking a
control measurement using a standard 60Co radiation source for the exact cell preparation
used in October 2008. Experience has shown that significant differences in response to
low LET radiation must be expected for different batches of the same cell line or when a
slightly different preparation of the gelatin is used. As we were forced to move the cell
preparation and analysis work from the University of Maastricht to the University
Hospital of Aarhus we cannot fully rely on earlier control measurements obtained in
2006.
To illustrate this point we show in figure 4 a preliminary analysis for the relative
biological effectiveness of antiprotons based on previous control measurements.
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Figure 4: Surviving fraction for V79 Chinese Hamster Cells irradiated with antiprotons plotted vs. dose
for peak and plateau. A biological endpoint of 10% cell survival is reached for 3.33 Gy in the peak and for
5.13 Gy in the plateau. Peak and Plateau RBE vary between 1.77 and 1.95 for the peak and 1.15 and 1.27 in
the plateau, depending on the choice of reference radiation. As the reference irradiations were done under
different conditions a repeat measurement with 60Co is needed to narrow down these ranges.
Dose values needed to achieve a biological endpoint of 10% cell survival was found
to be 3.33 Gy and 5.13 Gy in the peak and plateau respectively. For the previous control
samples the dose to achieve the same endpoint varied between 5.9 and 6.5 Gy and a final
control measurement using the exact same cell preparation is needed to finalize these
results.
In addition to completing the studies with V79 Chinese Hamster cells we continued
our studies using human cells (Type FaDuDD) started in 2006 with the goal to identify
specific genetic expressions as a result of the irradiation. The 2006 studies were intended
as an initial test if specific genetic expressions known in cancer therapy can be observed
and as this was the case, we mounted a more systematic study in 2007. 10 samples with
FaDuDD cells embedded in the same gel as used for the V79 cells were irradiated with
antiprotons at plateau doses between 0.75 Gy and 15 Gy. Samples of these irradiations
will in addition to genetic expression studies also be analyzed for survival.
 IV. Dosimetry Studies:
To interpret a measured response of a biological system exposed to a beam of hadrons
in terms of dose deposition, knowledge of the Relative Biological Effectiveness (RBE)
for the particular beam of particles is necessary. Similarly, for a radiation detector the
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relative effectiveness (RE) is relating the observed detector response with dose
deposition.
Attempts to measure the RBE directly in the peak region of an antiproton beam so far
have been problematic, since dosimetry of the antiproton depth dose curve is difficult due
to the unknown dosimeter response. Ionization chambers behave non-linear due to
volume recombination arising from the pulsed nature of the antiproton beam available at
CERN. Measurements using Boag’s theorem correcting for recombination effects have
been performed during the October 2006. The results of these studies have now been
finalized and a publication has been accepted and is in press. (See appendix B).
Our earlier measurements with Alanine detectors were augmented this year by
additional measurements and compared to the results of simulations using the particle
energy spectrum calculated by FLUKA and the track structure model of Hansen et Olsen
for conversion of calculated dose into response. Good agreement was observed between
the measured and calculated relative effectiveness although a slight underestimation of
the calculated values in the Bragg peak remains unexplained. The model prediction of
response of alanine towards heavy charged particles encourages future use of the alanine
detectors for dosimetry of mixed radiation fields. A paper on these studies has been
submitted to NIM B and has received positive reviews by the referees. A final version
with some changes and corrections requested by the referees has been sent to the editor
and final acceptance is expected very soon (see appendix C for the draft of this paper as
submitted).
 V.   Future Plans:
Depending final analysis of the data collected in 2008 we will define a scientific
program for 2008. Aside from augmenting existing data on V79 cells, if necessary, and
possible repeat experiments on the FaDuDD studies, we are discussing a number of
approaches to the third question raised in the introduction, the peripheral damage to cells
outside the direct beam. Again, our approach will be based on computer calculations with
a minimal but crucial set of experimental tests for benchmarking.
As for any measurements careful initial dosimetry studies are needed. We plan to
develop a program to beneficially use 1 week (7 days) of beam time performing several
independent measurements. The exact schedule for the requested beam time will need to
be decided within the collaboration to assure availability of laboratory space and
personnel, but currently we favor again the time period of late October, early November.
In order to impact the other experiments as minimal as possible we request to be
granted the last week of running time at the AD as last year. With the biological
preparations necessary and considering the limited survival time of the samples once the
cells have been harvested and embedded in gelatin, a precise schedule must be
established early on. The actual irradiation time can then be adjusted by a few days
within the week by waiting until the beam development is completed and dosimetry has
been fully established before preparing the actual samples from cell cultures started a few
weeks beforehand.
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 VI. Additions to the AD-4 Collaboration:
As of December 2007 a new Memorandum of Understanding between CERN and
the AD-4 collaboration has been executed by all current parties. Since then two new
institutions have joint the collaboration, the Queen’s University of Belfast,
represented by Prof. Robert McCullough, and the University of Athens, represented
by Prof. Angelo Angelopoulos. Amendments to the MOU reflecting these additions
are currently being drafted by the CERN Legal Service. A current list of institutions
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Antiprotons are are interesting as a possible future modality in radiation therapy for the following reasons: When fast
antiprotons penetrate matter, protons and antiprotons have near identical stopping powers and exhibit equal
radiobiology well before the Bragg-peak. But when the antiprotons come to rest at the Bragg-peak, they annihilate,
releasing almost 2 GeV per antiproton–proton annihilation. Most of this energy is carried away by energetic pions, but
the Bragg-peak of the antiprotons is still locally augmented with 20–30 MeV per antiproton. Apart from the gain in
physical dose, an increased relative biological effect also has been observed, which can be explained by the fact that
some of the secondary particles from the antiproton annihilation exhibit high-LET properties. Finally, the weakly
interacting energetic pions, which are leaving the target volume, may provide a real time feedback on the exact location
of the annihilation peak.
We have performed dosimetry experiments and investigated the radiobiological properties using the antiproton beam
available at CERN, Geneva. Dosimetry experiments were carried out with ionization chambers, alanine pellets and
radiochromic film. Radiobiological experiments were done with V79 WNRE Chinese hamster cells. The radiobiological
experiments were repeated with protons and carbon ions at TRIUMF and GSI, respectively, for comparison. Several
Monte Carlo particle transport codes were investigated and compared with our experimental data obtained at CERN. The
code that matched our data best was used to generate a set of depth dose data at several energies, including secondary
particle-energy spectra. This can be used as base data for a treatment planning software such as TRiP.
Our findings from the CERN experiments indicate that the biological effect of antiprotons in the plateau region may be
reduced by a factor of 4 for the same biological target dose in a spread-out Bragg-peak, when comparing with protons.
The extension of TRiP to handle antiproton beams is currently in progress. This will enable us to perform planning
studies, where the potential clinical consequences can be examined, and compared to those of other beam modalities
such as protons, carbon ions, or IMRT photons.c 2007 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology xx (2007) xxx–xxx.







54Antiproton therapy might sound like science fiction but in
fact, antiproton therapy may well be clinically beneficial for
selected cases and could perhaps be economically feasible
if performed in the context of a major facility producing
antiproton beams for fundamental science research. Gray
and Kalogeropoulus first suggested radiation therapy with
antiprotons in 1984 based on Monte Carlo calculation of a0167-8140/$ - see front matter c 2007 Published by Elsevier Ireland Ltd
Please cite this article in press as: Bassler N et al., Antiproton radiotherapsignificant enhancement of physical dose in the Bragg-peak
[1]. Sullivan shortly afterwards measured an enhancement
of the peak-to-plateau ratio of physical dose deposition by
antiprotons in polyethylene by a factor of 2 compared to
protons [2]. Since reducing normal tissue morbidity is one
of the main goals of radiotherapy, beam modalities such
as IMRT, proton beam therapy and carbon ion beams have. doi:10.1016/j.radonc.2007.11.028
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successfully implemented in clinical use [3–7]. Other parti-
cles, such as fast neutrons and pions, were applied in radi-
ation therapy, but proved to be less successful in the clinical
settings [8,9]. Antiprotons deserve closer investigation since
they exhibit the precision in dose delivery of a charged par-
ticle and confine the contribution of high linear energy

















































When fast antiprotons penetrate matter, they have the
same stopping power as protons. The amount of primary
particle loss is only slightly larger for antiprotons when com-
pared with protons, and is less than that of carbon ions [10].
As the antiproton comes to rest, it will preferably be cap-
tured by a high-Z nucleus. For a polystyrene target 99% of
the antiprotons will therefore annihilate on a carbon nucleus,
whereas the rest will annihilate with a hydrogen nucleus [11].
When captured by the target atoms, the antiproton will
immediately spiral towards the nucleus and annihilate on its
surface. This annihilation process releases 1.88 GeV corre-
sponding to twice the rest-mass of the proton and the energy
release is converted on average into 4 or 5 pions [12,13]. The
pions created are p+ andpparticles, aswell as p0. The p0me-
son is highly unstable anddecays instantaneously into highen-
ergy gamma-rays with roughly 70–300 MeV [12]. Due to the
solid angle covered by the nucleus, 1 or 2 of the charged pions
are most likely penetrating the nucleus inducing an intra-nu-
clear cascade, causing the nucleus to break into fragments
[14–16]. Charged fragments have a very short range in the
target and will deposit their kinetic energy in the immediate
vicinity of the annihilation vertex. Also, we expect that some
of these fragments will exhibit a high-LET and are responsible
for an increase in biological effectiveness of antiproton anni-
hilation compared to protons stopping in the target. Antipro-
tons annihilating on particles heavier than protons will also
produce neutrons which will have a larger range and will lead
to a certain level of background radiation. This needs to be
studied carefully in the context of validating antiprotons for
radiotherapy applications.
The total energy deposited locally by these particles has
been estimated by Gray and Kalogeropoulos using Monte
Carlo calculations [1] to be 30 MeV per antiproton, which
has been confirmed experimentally by Sullivan [2] who used
a continuous beam of antiprotons from the Low Energy Anti-
proton Ring (LEAR) at CERN and standard ionization cham-
bers. This energy represents an increase of the physical
dose deposition in the Bragg-peak by roughly a factor of 2,
when compared to protons. In addition to this augmentation
of the physical dose the secondary particles also cause the
antiproton beam to have different radiobiological proper-






Currently, only few laboratories in the world produce





beam of antiprotons at clinical relevant energies is avail-
able. Antiprotons are produced from a 26 GeV proton beam,
which is being dumped into a target. The peak production
occurs at an antiproton energy of 3.6 GeV. Antiprotons are
collected at this production energy in the antiproton decel-
erator (AD) ring, decelerated to lower energies, and cooled
using stochastic cooling as well as electron cooling to de-
crease beam emittance. To date we have used both a
47 MeV and a 126 MeV antiproton beam, which have a range
of approximately 2 or 11 cm in a water phantom, respec-
tively. Every 90 s around 3 · 107 antiprotons are delivered
to our experiment, which corresponds to a dose in the pla-
teau region of 30 mGy at r = 4 mm of the Gaussian shaped
beam at 126 MeV. These antiprotons exit the accelerator
vacuum through a 15 lm titanium window and pass several
non-destructive beam monitors before entering the biologi-
cal target. A fast current transformer gives the total charge
extracted from the accelerator and a combination of a thin
scintillator and a CCD camera can be used to monitor the
beam position and profile. The antiproton beam focus can
be changed, depending on the experimental requirements,
between r = 4 mm and r = 15 mm. A future antiproton pro-
duction facility for experimental physics is planned at the
Gesellschaft fu¨r Schwerionenforschung (GSI) in Darmstadt
and will offer significantly higher beam intensities.T
ERadiobiologyIn 2006 we published an article concerning the radiobiol-
ogy of a 47 MeV antiproton beam, describing the initial
experiments carried out at CERN in 2003 and 2004 [17].
RBE determination was at that time not possible, since we
could not assess the absolute physical dose for the pulsed
antiproton beam. Instead the Biological Effective Dose Ratio
(BEDR) term was conceived. Recently we have initiated a
new set of measurements at higher energy at CERN and at
GSI to compare the biological effects of antiprotons and
carbon ions using identical experimental conditions. The en-
ergy used of 126 MeV provides a better separation of the
peak from the plateau region and also enables us to produce
a clinically relevant spread-out Bragg peak (SOBP). After
careful dosimetry studies (see next section), we are now
able to adequately assess the absolute physical dose in
the peak region of the pulsed antiproton beam. This will en-
able us to directly determine the RBE in the peak region in
future experiments, which then can be used as an input
parameter for computer models used for treatment
planning.Dosimetry
Monte Carlo simulations with FLUKA 2006.3 [18,19] of a
pristine beam of antiprotons are shown in Fig. 1. Here a
5 · 5 cm square field of 502 MeV/c (126 MeV) antiprotons
on a water target was simulated. The dose was scored along
the central beam axis in circular disks with a diameter of
2 cm in 0.5 mm steps. The beam momentum spread was
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Fig. 1. FLUKA simulation of the depth dose distribution of a square 5·5 cm 126 MeV antiproton field, scaled to 1010 antiprotons. The dose was
averaged over a central cylindrical region with a diameter of 2 cm in steps of 0.5 mm.
1 From pion decay.
2 A few R-particles were also encountered during the simulations.
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Rmimicking the parameters of the beam at CERN. The FLUKAstatistics were 500.000 simulated antiprotons, but the dose
plotted here is scaled to 1010 antiprotons. Neutrons do not
contribute directly to dose, as these particles are indirectly
ionizing. They generate recoils which are further trans-
ported by FLUKA, if the energy is sufficiently high. Dose
from electrons and positrons generated by photons is con-
tained in the curve labelled ‘‘Electromagnetic’’. The curve
labelled ‘‘Recoils’’ represents dose contributions from
unspecified fragments with low energy (order of keV) which
are not transported. They make up roughly 8% of the total
dose near the annihilation peak. The asterisk in e.g.
‘‘Li-*’’ refers to all isotopes of Lithium (see Fig. 2).
Fig. 1 thus gives an overview of the contributions to the
total dose. The primary antiproton beam (which, by the
way, is almost identical to the depth dose curve of a primary
proton beam) deposits most dose, followed by contributions
from secondary protons, pions, EM-transport and helium nu-
clei. The remaining contributions are significantly less, and
have been plotted on a logarithmic y-axis, else they were
indistinguishable. The secondary particles are mainly cre-
ated at the end of flight, and then emitted isotropically,
which explains the symmetry of the curves at the annihila-Please cite this article in press as: Bassler N et al., Antiproton radiotheraption vertex. Also, interesting enough, the dose contribution
by transported fragments heavier than helium is in the same
order as the dose contributions from muons 1 and the rather
exotic kaons2.
Dosimetry of an antiproton beam is not trivial due to the
mixed particle spectrum of the secondary particles from
antiproton annihilation. Most, if not all, solid state detec-
tors respond non-linear when subjected to high-LET ionizing
radiation. Often the response depends on energy and charge
of the particle, and usually the behaviour of such detectors
requires a detector model that describes the performance
in mixed particle radiation fields. Initially, alanine detec-
tors, thermoluminescent devices (TLDs), and radiochromic
films were applied in the beam. We found that alanine
detectors [20,21] could be used as an absolute dosimeter
in the plateau region, and to some extent in the mixed par-
ticle environment around the annihilation peak. A model for
the response of the alanine detector in various mono-ener-
getic fields was used in conjunction with Monte Carlo simu-
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response of alanine to the antiproton beam thus calculated
was in good agreement with the measured response. This
work is subject of a forthcoming publication [22].
Apart from alanine detectors, we found that dosimetry
with TLDs is not recommendable due to the lack of ade-
quate LET models and standardised handling procedures of
the detectors, which compromised the reproducibility of
the response in particle fields [23]. Radiochromic films were
until now primarily used for determining the width of the
beam, as well as the position of the annihilation peak, but
not for dosimetry, again due to the lack of models which
can translate the response into dose for mixed particle
spectra. Still, Fig. ? shows effectfully the key differences
between a proton and antiproton beam: here two slanted
radiochromic films were exposed to a Gaussian shaped beam
of protons and antiprotons, respectively, entering from the
left. The beam was spread-out to cover a few mm in the tar-
get region. The colour scale is normalized to match both the
background and peak dose levels. Clearly, the penumbra
due to secondary particles being emitted from the antipro-
ton annihilation can be seen. Secondly, for iso-response in
the peak region, the response in the entry region for the
antiprotons is significantly less pronounced.
Relative dosimetry was done with a transmission ioniza-
tion chamber (Advanced Roos Chamber from PTW Freiburg).
Absolute dosimetry for the biology experiment using the
ionization chamber alone was not possible, since the
40 mm diameter of the Advanced Roos Chamber was much
larger than the 10 mm FWHM3 of the antiproton beam.
Small beam misalignment and changes in FWHM, which seri-
ously impact the dose delivered to the test sample, cannot
be detected by the ionization chamber. Instead, the ioniza-
tion chamber was used for relative dosimetry only. Due to
the pulsed structure of the antiproton spills (one 300 ns spill
every 90 s), it is necessary to compensate for ionic recombi-
nation effects [24,25]. The results of the ionization cham-
ber measurements were compared with the Monte Carlo
particle transport programs SHIELD-HIT v. 2.2 by Sobolevsky
et al. [26] and FLUKA 2006.3. FLUKA proved to be in excel-
lent agreement with our relative ionization chamber mea-
surements, which is shown in Fig. 3, and therefore FLUKA3 The FWHM is selected to be sufficiently large to give a
reasonably homogeneous dose across the sample tube (which had
a diameter of 6.5 mm), while still being small enough in order to
use as much as possible of the antiproton beam.
Please cite this article in press as: Bassler N et al., Antiproton radiotherapOwas chosen to build the input data needed for the treatment
planning software TRiP [27,28]. A paper concerning these






The scarcity of antiprotons (we typically have access to
the antiproton beam at CERN for just one week per year)
dictates that we concentrate our measurements on produc-
ing the necessary database to validate our Monte Carlo
codes. Then we use these codes to generate the set of input
data needed for a biological treatment planning system to
generate a dose plan for a virtual treatment with antipro-
tons that can be compared with a treatment plan calculated
for protons, carbon ions, or other modalities. To date we
have used TRiP to model physical dose distributions based
on the depth dose base curve for antiprotons generated with
FLUKA and compared this to a physical dose distribution for
a carbon ion beam.
Fig. 4 is comparing a carbon ion treatment plan (left)
with an antiproton plan (right). The plan is only optimized
for physical dose at this time. Comparing these plans, one
can see that the dose in the entry region is reduced,
whereas the lateral penumbra is slightly more pronounced
for antiprotons. It is still too early to derive conclusions
from this, since the radiobiology optimization is still under
development for antiprotons, and the RBE is expected to
vary significantly along the depth dose curve for antipro-
tons. TRiP already uses the Local Effect Model (LEM) [30–
32] for optimizing the biological dose for carbon ion beams.
To optimize the treatment plan for biological dose for anti-
protons, the complete particle-energy spectrum is needed
for LEM to model the RBE. We have generated such spectra
using FLUKA and are currently implementing these in our
calculations. This will enable us to study a variety of clinical
situations in order to identify those cases where antiproton




So far the arguments for and against antiproton radio-



















































Fig. 3. FLUKA 2006.3 calculated relative dose compared with CERN ionization chamber measurements.
Fig. 4. Physical dose distributions for a single field of carbon ions (left) and antiprotons (right). For antiprotons the entrance dose is noticeably
reduced while the lateral penumbra is slightly increased. These calculations do not include any biological effects.
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Rments performed by the AD-4/ACE collaboration at CERN
have shown an enhanced biological effect of 4 in the peak
region for antiprotons compared with protons for the same
entrance dose. Careful antiproton dosimetry experiments
and tests of various Monte Carlo codes have resulted in reli-
able computer simulations of clinical antiproton beam dose
distributions. Combined with the data from the cell survival
experiments the RBE can be calculated in future experi-
ments and can then be implemented in biological treatment
planning systems.
The expected possible advantage of antiproton therapy
over other advanced modalities like combined IMRT/IMPT
(protons)/IMPT (carbon ions) is still to be examined in treat-
ment planning studies. One advantage of antiprotons is low-
LET in the plateau (and thereby low alpha/beta ratio for
late responding normal tissue) combined with high-LET, high
RBE and low OER in the peak region for small targets. This
suggests that antiproton therapy could be superior for small
radioresistant targets surrounded by highly radiosensitive
critical normal tissue. This could obviously be re-treatment
of local failures in previously irradiated organs and tumours
like chordomas or chondrosarcomas located between thePlease cite this article in press as: Bassler N et al., Antiproton radiotherapoptical pathways and close to the optic chiasm. Other antic-
ipated uses are boost to hypoxic areas where IMRT and IMPT
(protons and carbon) probably could not give the same BED
conformity as fractionated antiproton therapy; this is again
especially relevant in tumours surrounded by critical normal
structures like hypoxic components in paranasal squamous
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Abstract
We have measured the depth–dose curve of 126 MeV antiprotons in a water
phantom using ionization chambers. Since the antiproton beam provided by
CERN has a pulsed structure and possibly carries a high-LET component
from the antiproton annihilation, it is necessary to correct the acquired charge
for ion recombination effects. The results are compared with Monte Carlo
calculations and were found to be in good agreement. Based on this agreement
we calculate the antiproton depth–dose curve for antiprotons and compare it
with that for protons and find a doubling of the physical dose in the peak region
for antiprotons.
(Some figures in this article are in colour only in the electronic version)
1. Introduction
The basic idea of antiproton radiotherapy (Gray and Kalogeropoulos 1984) is to utilize the
energy from the antiproton–nucleus annihilation reactions, which occur when the antiprotons
come to rest. Antiprotons behave similar to protons at high velocities, but when they slow
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down in the target material, they are captured by a nucleus and annihilate on its surface.
Hereby twice the rest mass of the proton mp is released (1.88 GeV) at the end of the particle
trajectory. The probability for photo-emission similar to that known from the positron–electron
annihilation is rather small. Instead, on average 4–5 π -mesons are created (Inokuti 1989).
The photons observed from the antiproton annihilation arise primarily from π0 decay, which
has a lifetime in the order of 10−16 s. The energy of these photons is between 70 and 300 MeV
(Agnew et al 1960). For antiproton–nuclei reactions, there is a high probability that one or
more π -mesons will strike the nucleus7. Those entering the nucleus will start an intra-nuclear
cascade, knocking out light nuclei (Markiel et al 1988). When antiprotons enter a chemical
compound consisting of several materials, the majority of the annihilations will take place
on high-Z materials (Ponomarev 1973). For example, in the case of polystyrene only 1% of
the antiprotons will annihilate on hydrogen with the remaining 99% annihilating on carbon.
Antiprotons annihilating on tissue-like material are expected to produce a particle spectrum
featuring pions, neutrons, protons, deuterons, heavier nuclei and photons. A few kaons may
also be created (Agnew et al 1960, Polster et al 1995). Most of the 1.88 GeV released is
carried away from the annihilation vertex by the long-ranging particles (high-energy pions,
protons, neutrons, and photons), but roughly 30 MeV is deposited locally near the annihilation
vertex (Sullivan 1985). Even though this sounds at first sight disappointingly low (Sullivan
1985, Inokuti 1989), it represents a doubling of the peak dose at the end of the antiproton
particle track, compared to protons, producing a significant clinical advantage. The loss of
the primary beam due to in-flight nuclear reactions is expected to be slightly more than for
protons, but still less than that of carbon ions (Bassler et al 2005). The antiproton depth–dose
curve will therefore look similar to the depth–dose curve of protons, but with additional energy
deposited in the Bragg peak from the antiproton annihilation.
Since 2002 the AD-4/ACE Collaboration has been working at CERN, using the antiproton
decelerator (AD), on assessing the dosimetric and radiobiological properties of beams of
antiprotons in order to estimate the suitability of antiprotons for radiotherapy (Holzscheiter
et al 2004, 2006, Maggiore et al 2004, Bassler et al 2006, Bassler 2006). The AD has been
designed and constructed for fundamental research on matter–antimatter symmetries and the
availability of antiprotons for applied studies is sparse at best. Typically, we are able to
obtain one week of beam time each year and have therefore concentrated on collecting few
but critical data to benchmark computer models that can then be used to develop treatment
planning tools. These in turn will allow us to gain a deeper insight in the potential advantages
of antiprotons compared to other modalities and in selecting the most appropriate candidates
of tumour indications for antiproton therapy.
Radiotherapy with antiprotons has a potential to deliver a high biological effective dose to
the target while at the same time reducing the dose to normal tissue in the entrance region much
more than possible with any other radiation modality. It is one of the paradigms of radiotherapy
that a decrease of the irradiated volume of normal tissue is in many cases associated with an
increased tolerance dose of these tissues (see, e.g., Hopewell and Trott (2000)). There are at
least two situations in which antiprotons might be useful for radiotherapy. The first are tumours
that cannot be controlled by conventional radiation, because the applied dose is limited by
the surrounding normal tissues and where a substantial dose escalation may be beneficial,
like e.g. tumours at the base of skull or paraspinal tumours. Another indication may be
recurrent tumours. If the initial treatment included any kind of radiotherapy, the normal tissue
surrounding the tumour will have already received a significant dose. In order to re-irradiate
7 For nuclei with 60 A  200 the probability is 85–90% according to Cugnon et al (2001).
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Figure 1. FLUKA calculation of charged particle LET spectrum of a 126 MeV antiproton
beam. The spectrum was calculated both in the peak region and in the plateau region. Charged
particles with 1  Z  6 were here taken into account. The sharp line in the plateau region at
0.6 keV µm−1 originates from the primary antiproton beam.
this tumour one needs to assure that the dose to normal tissue does not exceed accepted
tolerance level. This is facilitated by the high peak-to-plateau ratio offered by antiprotons.
Unlike protons, the relative biological effectiveness (RBE) of the antiproton beam varies
sharply with depth near the end of range, as the annihilation process yields fragments with a
higher linear energy transfer (LET). A calculated LET spectrum is shown in figure 1.
This enhanced LET results in an increased RBE in the peak region relative to the plateau
region. The biological effect of an antiproton beam was for the first time measured by
Holzscheiter et al (2006). However the RBE in the peak could not be measured, since
the dosimetry in this region was complicated by both the mixed particle spectrum and the
pulsed form of the antiproton beam. Dosimetry with alanine, thermoluminescent devices and
radiochromic films were used, but these suffer from a strong, often not well understood, LET
dependence of the response. Calorimetric measurements were considered as too cumbersome.
Ionization chamber measurements were initially believed to be complicated due to the pulsed
structure of the antiproton beam currently available at CERN.
In this paper, we report the first measurement of the dose deposited in water by a pulsed
antiproton beam using ionization chambers. The high instantaneous dose rate causes a
reduction in the charge collection efficiency due to general recombination effects. Using
the ‘Boag’s two voltage method’ as described by Boag and Currant (1980) we can get an
estimate of the charge collection efficiency. It should be stressed that our goal is not to
perform high precision dosimetry, as there are several sources of errors in the 1% range that
may perturb the results which we cannot yet control. Our primary goal is instead to obtain
an initial estimate of the RBE for antiprotons that will allow us to define any significant
advantages of antiproton radiotherapy over other modalities. For this, uncertainties in dose of
a few per cent may be tolerated.
2. Experimental methods
The antiproton decelerator (AD) at CERN is set up to provide a 502 MeV/c (∼126 MeV)
antiproton beam. Every 90 s a spill of roughly 2–3 × 107 antiprotons is ejected within 300 ns.
The average number of ejected antiprotons may change depending on the actual state of the
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accelerator facility. Using, e.g., arbitrarily selected 20 consecutive spills (corresponding to
about 30 min of operation), the average amount of antiprotons per spill was 2.5 × 107 with a
standard deviation of 0.1 × 107. The number of antiprotons for each spill was recorded for
each individual spill using a sensitive current transformer in the extraction beam line from
the AD to our target station. While the statistical fluctuations of these measurements are low,
particle loss between the transformer and our target may introduce a systematic shift (10%).
The momentum spread of the beam was p/p = 5 × 10−4, and the divergence is in the order
of 5 mrad. The FWHM of the beam was slightly ellipsoid, being about 1 cm in one axis
and 0.9 cm along the other axis. The beam exits the accelerator vacuum via a thin titanium
window, traverses several beam monitors (scintillator viewed by CCD camera, radiochromic
film) and is collimated to 1 cm diameter before entering our target. The temperature in the
AD hall is maintained at 20 ◦C.
The target phantom is a 220 mm × 275 mm × 180 mm water tank built of PMMA material
according to IAEA and ICRU standards for proton therapy (IAEA 2000, ICRU 1998). The
PMMA walls are all 10 mm thick, except for the entrance window, which is 3 mm thick and
had a diameter of 70 mm. We use two custom-made plane-parallel ionization chambers of the
advanced Roos type from PTW Freiburg with graphite electrodes8. These are similar to the
standard Roos chamber M34001, but with an increased diameter of 39.6 mm and a collecting
volume of 2.479 cm3. The electrode spacing is 2.013 mm. The ionization chambers are cross
calibrated in absorbed dose to water using 60Co γ -rays as reference radiation quality at +
400 V towards a reference ionization chamber using the in-house gammatron at the German
Cancer Research Center (DKFZ) in Heidelberg (Kartal 2007). The calibration is carried out
with a 10 cm × 10 cm field in a water phantom at 20 ◦C temperature and air pressure of 1013
hPa. The source–chamber distance was 80 cm and the measurement depth in water was 5
g cm−2 for the effective point. The reference chamber is a PTW Roos ionization chamber
M34001-0045 and is calibrated at PTW, which is a Secondary Standard Dosimeter Laboratory
(SSDL). The NQ0 is found to be 1.32 × 107 Gy C−1 for both ionization chambers with an
uncertainty of ±4%.
The measurement in the antiproton beam was performed using a pencil beam which had a
diameter that was much smaller than the active area of the chamber. The dose obtained under
such conditions is an integral dose over the area of the chamber at the specific depth rather
than a central axis depth dose which is measured in a broad beam. Measuring such an integral
dose is common for facilities using, e.g., a scanned pencil beam, like at the Paul-Scherrer
institute or at GSI for carbon ions.
At the antiproton beam line at CERN, one ionization chamber is attached in front of the
entrance window to the water phantom. This chamber is used for normalization of the pulse to
pulse fluctuations of the antiproton beam. The second chamber is attached to a calliper which
provides submillimetre precision readings of the ionization chamber position. The collected
charge is read out with a UNIDOS electrometer from PTW Freiburg.
At each calliper position, data from each of several spills of antiprotons are recorded.
Typically, we see around 175 pC per spill in the entry chamber and 0.2–1.4 nC in the second
ionization chamber depending on the position in the water phantom. The fixed ionization
chamber at the entrance window is kept at +400 V at all times. With the ionization chamber
mounted in the water phantom we usually record 4–8 spills at +400 V and 4 spills at +300
V. The electrometer is read out and reset after each spill. The dark current contribution was
insignificant.
8 TM34073-1, 08-0001 and -0002.
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From the measured charge q1 and q2 recorded at V1 = 400 V and V2 = 300 V, respectively,





− ln(1 + u1)
ln(1 + u1V1/V2)
. (1)
Equation (1) is derived from equation (9) in (Boag and Currant 1980). u is related to the
collection efficiency f in such a way that
f = 1
u
ln(1 + u). (2)
In practice, a plug-in was written9 for the ‘Gnumeric’ spreadsheet program10, which
extended the software with additional functions for calculating u and f . As an input parameter
the measured charges at two voltages are needed. The functionality of the algorithms was
checked by comparing the results with another independently developed program using the
root-finding function provided by the Gnu Scientific Library (Galassi et al 2007).
Alternatively, Boag et al also suggest three different algorithms in Boag et al (1996) which
enhance equation (2) with a free-electron collection effect on the recombination correction.
These three algorithms are also supported in the plug-in mentioned before. In these algorithms,
the free-electron fraction p is needed as an additional parameter. In this paper, f ′ will be the
free-electron-corrected charge collection efficiency based upon equation 7 in Boag et al (1996):




At some calliper positions, we only measure charge at one voltage setting (400 V).
Here, the charge collection efficiency is interpolated from neighbouring positions. Beyond the
annihilation peak the acquired charge is small and equation (1) has no solution due to statistical
fluctuations, and instead the collection efficiency is extrapolated. Similarly for the ionization
chamber at the fixed entry position, the charge collection efficiency is merely estimated by
extrapolation.
Linearity checks validating Boag’s two voltage method are made at two calliper positions,
covering the peak and the plateau region. Here the entire voltage range from the UNIDOS
electrometer is applied in 50 V steps, and the q−1 versus V −1 plots are investigated for linearity.
The Boag-corrected collected charge MQ,B of the antiproton beam quality Q can be found
by
MQ,B = q/f. (4)
The absolute dose DQ is then
DQ = MQ,BNQ0kQ,Q0 (5)
where NQ0 is the 60Co calibration factor, as mentioned earlier. kQ,Q0 is a beam quality
correction factor, which here is set to unity. The kQ,Q0 factor for the advanced Roos chamber
should be nearly identical to the corresponding factor for the standard Roos chamber, the
only possible difference being the chamber specific correction factors pQ appearing in the
calculation of kQ,Q0 (according to equation (3.4) of IAEA (2000)). This pQ factor is, however,
taken to be unity for all chambers in a proton beam in IAEA (2000) and for photons the only
effect of an increased diameter could influence the perturbation effect of the wall, pwall, which
is given as 1.001 for the Roos chamber. Given the large guard ring of the Roos chamber this
factor should be dominated by the entrance and exit window of the chamber. Any expected
9 The plug-in is available at http://www.phys.au.dk/˜bassler/work.shtml?Boag.
10 http://www.gnome.org/projects/gnumeric/.
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difference for our chamber should not exceed the 1% level, an accuracy that is clearly beyond
the level of accuracy we are aiming for in our experiment. A difference in kQ,Q0 for protons
and antiprotons may arise due to the different spectra of secondary particles. Even for carbon
ions, where secondary particles may play a similarly important role as for antiprotons, kQ,Q0
is still assumed to be of the same range as for protons, namely 1.003. Taking kQ,Q0 as unity
for antiprotons is thus not expected to introduce an uncertainty of more than 1–2%.
The relative measurements plotted in figures 5 and 6 are the ratio between the Boag-
corrected charge measured in the ionization chamber mounted on the calliper MQ,B,var(d) at a
given depth d and the charge measured in the entry ionization chamberMQ,B,entry corresponding








As mentioned earlier, the average ratio was acquired from multiple spills. The absolute
measurements presented in the third column in table 1 is the dose per antiproton, calculated
using equation (5) and the number of antiprotons derived from the beam current monitor. The
dose per antiproton presented here is averaged over multiple spills as well, and the standard
deviation of the measurement is mentioned in the table as well.
3. Monte Carlo calculations
For comparison, calculations using both FLUKA v. 2006.3 (Fasso` et al 2005, eConf
C0303241:MOMT005 2003) and SHIELD-HIT v2.2 (Gudowska et al 2004) are applied. The
geometry applied in FLUKA and SHIELD-HIT consists simply of a 502 MeV/c antiproton
beam hitting a 20 × 20 × 20 cm3 water tank. The Gaussian-shaped beam width was set to
have a FWHM of 1.0 cm and 0.9 cm along the x- and y-axes. For statistical precision we used
150 000 and 100 000 primary particles, respectively, in the calculations using FLUKA and
SHIELD-HIT.
The scoring region is a stack of discs placed along the beam axis. Each disc has a diameter
of 39.6 mm matching the effective diameter of the ionization chamber. Since the FWHM of
the beam width is only in the order of 1 cm, practically all antiprotons are contained in the
active scoring region, even in the Bragg peak. This is illustrated in figure 2 which shows the
lateral dose profile for the simulated beam in the plateau and the peak regions. The active
scoring region also includes most low energy fragments generated in the annihilation events.
The resolution along the beam axis was in 1 mm steps for the SHIELD-HIT simulation
and 0.25 mm for the FLUKA simulation. For all FLUKA calculations a beam momentum
spread of p/p = 5 × 10−4 was used as well as a beam divergence of 5 mrad, corresponding
to the characteristics of the CERN beam. In FLUKA, the default transport settings and cut-off
energies from the ‘HADROTHE’ card are always used.
For comparison with protons (shown later in figure 7), the FLUKA calculation was
repeated using a 5 cm × 5 cm square field of antiprotons, while maintaining beam energy,
momentum spread and divergence. The target was a 20 × 20 × 100 cm3 water tank placed
along the beam axis. The average dose is again scored along the beam axis using flat discs,
but with a radius of 0.5 cm and a thickness of 0.25 mm. Here, 400 000 particles are simulated.
Finally, the LET spectrum shown in figure 1 was obtained using 400 000 particles in a
water phantom. Again, the primary beam was a 5 cm × 5 cm square field of antiprotons with
unchanged beam energy, momentum spread and divergence. The track-length fluence was
scored for pions and kaons (π+, π−, π0, K+, K−, K0), for protons and antiprotons, as well as
all other nuclei with 1  Z  6. The scoring region was one 2 × 2 × 1 cm3 box placed at
The antiproton depth–dose curve in water 7
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Figure 2. FLUKA calculation of the lateral dose distribution at 1.1 cm WE depth and 11.6 cm
depth for the CERN beam. The entire beam is confined within the diameter of the ionization
chamber.
the entrance to the water phantom in the centre of the beam with the short sides parallel to the
beam axis. A similar scoring volume is also positioned around the centre of the annihilation
peak at a depth of 11–12 cm.
Initial attempts to use Geant4 (Allison et al 2006, Agostinelli et al 2003) failed, as at
that time the behaviour of very low energy antiprotons had not yet been fully incorporated.
Meanwhile much progress in this area has been made (Kossov 2005) and future studies may
include Geant4 simulations.
4. Results
The 1/q versus 1/V plot in the plateau and at the peak of the depth–dose curve is shown in
figure 3. The data were normalized to 1/q acquired at 400 V. The choice of 400 and 300 V
for the ionization chamber may not be ideal, as it is often suggested that V1 > 2V2. However,
these voltage setting are within the region of linearity for the entire depth–dose curve, thereby
maintaining a consistent read-out procedure.
The calculated charge collection efficiency, f , which was applied to the measured charge,
is shown in figure 4 as a function of WE depth. Using the charge collection efficiency data,
we can compare the measured depth–dose curve in water with SHIELD-HIT and FLUKA
simulations, which is shown in figures 5 and 6, respectively. Since the measurements were
recorded with an arbitrary x-scale, the measurements were shifted along the x-axis in order
to match the peak of the Monte Carlo calculations. Both the Monte Carlo calculations and
the measurements are normalized to unity at 88 mm WE depth in order to better show the
deviations in the form of the depth–dose curve. Using this normalization, the SHIELD-HIT
calculations show an overestimation of more than 20% in the peak region, whereas FLUKA
matches the measured depth–dose curve very well (1%). In the plateau region at 38.5 mm
WE depth SHIELD-HIT underestimates the relative dose with 16%. FLUKA overestimates
the dose here with less than 2%.












q(V=400)/q = 0.957 + 15.8 * 1/V
q(V=400)/q = 0.957 + 15.0 * 1/V
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q(V=400)/q = 0.916 + 46.5 * 1/V
q(V=400)/q = 0.830 + 68.0 * 1/V
Figure 3. 1/q versus 1/V plots. Left figure shows data acquired in the plateau region, the right
figure is acquired in the peak region. Results are normalized at 1/q (V = 400).
Figure 4. Calculated charge collection efficiency.
In terms of absolute values, our measurements indicate higher doses than calculated with
SHIELD-HIT or FLUKA. With the entry ionization chamber we measure on average 101 ±
4 pico Gy (pGy) deposited dose per antiproton. As an estimate, we extrapolate the charge
collection efficiency from the first data points of the second ionization chamber. At the second
ionization chamber we see 116 ± 2 pGy of deposited dose per antiproton in a WE depth of
28 mm and 166 ± 3 pGy at a WE depth of 88 mm. In table 1, we compare these values to those
calculated by SHIELD-HIT and FLUKA. The errors stated here are 1σ standard deviations.
The free-electron effect was calculated at a point in the plateau (at 28 mm WE depth)
and the peak region (at 116 mm WE depth) assuming p = 0.1. The results are presented in
table 2.
All data and data analysis are made available on the world wide web (Bassler et al 2007).
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Figure 5. 126 MeV antiprotons hitting a water target. SHIELD-HIT v.2.2 Monte Carlo calculations
compared with ionization chamber measurements.
Figure 6. 126 MeV antiprotons hitting a water target. FLUKA 2006.3 Monte Carlo calculations
compared with ionization chamber measurements.
Table 1. Absolute comparison of deposited dose per antiproton.
SHIELD-HIT FLUKA Measurements
(pGy) (pGy) (pGy)
Entry chamber at 0 mm 86.7 96.7 101 ± 4
Chamber at 27.5 mm 94.5 109 116 ± 2
Chamber at 87.5 mm 147 152 166 ± 3
5. Discussion
We found excellent agreement between ionization chamber measurements and FLUKA
simulations for relative dose and reasonable agreement in the plateau regions for absolute
dose (error < 4–9%). The origin of the systematic deviation between experiment and models
is not clear, but may possibly be attributed to several sources: first, the advanced Roos chamber
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Table 2. Collection efficiency without (f ) and with (f ′) free-electron correction; p = 0.1.
u f f ′
Chamber at plateau (27.5 mm) 0.0466 0.9774 0.9797
Chamber at peak (115.5 mm) 0.4736 0.8186 0.8383
was cross calibrated towards another ionization chamber which has an uncertainty of ±4%
(Kartal 2007). Second, the calibration of the antiproton beam current monitor (which provides
the amount of antiprotons) is accurate to only ±1% and may additionally have a systematic
deviation of up to 10%. The difference in results from SHIELD-HIT and FLUKA is most
likely related to different in-flight annihilation cross sections used by the two code packages.
The in-flight annihilation cross sections of antiprotons and in-flight losses of other ions are
discussed in more detail in Bassler et al (2005).
From the presented data it is difficult to decide which of the two code packages gives
a more accurate value for the absolute antiproton dose. But based on the better agreement
of the relative dose versus depth and on the fact that FLUKA simulations of protons were
benchmarked by Biaggi et al (1999) and found in very good agreement with measurements,
we tend to favour the FLUKA code package.
Finally, there is an uncertainty coming from the application of Boag’s theory to the
antiproton beam. The correction used is strictly valid only if the linearity of the 1/q versus
1/V plot is maintained. In figure 3, the plateau position plot reveals a deviation from linearity
at a chamber voltage of 400 V. But when using points from 350 V and below, this only changed
the charge collection efficiency by roughly 1.5%. The data in figures 5 and 6 are exclusively
based on charge collected at 400 V and 300 V.
For pulsed beams both initial and general recombination show a linear 1/q versus 1/V
dependence (Palmans et al 2006). In principle, it is possible to distinguish the contributions
from both recombination effects. By varying the pulse length, only the general recombination
is affected, as initial recombination is independent of the incident dose rate (Park et al 2006).
Since it is not possible to significantly change the pulse length at the CERN beam line, one
could instead change the angle of the ionization chamber relative to the beam axis. This was
done by Kanai et al (1998) for a heavy ion beam, which also investigated the LET dependence
of initial recombination. It could be interesting to apply similar methods to the antiproton
beam in a future experiment and perhaps derive an estimate of the mean LET of the particle
spectrum.
The result from Boag’s free-electron-correction term in table 2 indicates only small
changes to the result. The change of the charge collection efficiency when applying f ′ instead
of f is less than 1% in the plateau region and 2% in the peak region. The other two models in
Boag et al (1996) gave similar results within ∼ 1%. The estimate of p = 0.1 was derived from
figure 3 in that reference. Here, p is plotted as a function of V for a plane-parallel ionization
chamber with an electrode distance of 6.1 mm. Assuming equal field strength in the ionization
chamber we read out p for a corresponding electrode distance of 2 mm. As a test, we tried
to minimize the sum-of-squares deviation between measurement and FLUKA calculation and
use p as a free parameter. A best fit was then achieved at p = 0.062, but this is regarded as
being highly speculative.
At last, one may discuss whether the Bragg–Gray conditions are fulfilled for an antiproton
beam. Antiprotons annihilating on the air in the ionization chamber may lead to the generation
of new particles, leading to a violation of the charged particle equilibrium requirement.
The antiproton depth–dose curve in water 11
0 2 4 6 8 10 12 14






























Figure 7. Comparison of the central axis depth–dose curves in water from a pristine antiproton
beam with a similar proton beam. The depth–dose curves were calculated with FLUKA. The
energy of the antiprotons was 126 MeV, and the field size was 5 cm × 5 cm. The momentum
spread was assumed to be p/p = 5 × 10−4 and the beam divergence was set at 5 mrad. The
dose was scored along a cylindrical region with a diameter of 1 cm in 0.25 mm steps.
Those particles may have different energy spectrum and composition. But as air mostly
consists of light elements such as oxygen and nitrogen which are comparable to carbon11
and the water environment, we do not expect significant deviations here. Despite the various
uncertainties mentioned above, the overall agreement between FLUKA and our experimental
data provides us with a reasonable level of confidence that we can determine dose–depth curves
for antiprotons with sufficient accuracy to obtain RBE values versus depth for an antiproton
beam using the measured survival values obtained in previous (Holzscheiter et al 2006) and
future experiments conducted at CERN.
If the dosimetric evaluation is confirmed further, this will emphasize the potential of
antiprotons in radiotherapy compared to protons, as presented in figure 7. Here, we used a
broad beam (5 cm × 5 cm) in order to more closely match a clinical situation. In principle,
this beam could be produced passively or actively to cover the target area. Scoring the central
dose region, several features can be observed. In the entry region, a slight elevation of the dose
level is seen as compared to protons, arising from antiprotons annihilating in-flight. The peak
region itself is augmented by a factor of more than two as compared with the proton Bragg
peak, at iso-fluence. When peak normalizing the depth–dose curves shown here, the dose
from antiprotons at a depth of 6 cm will only be half that of the dose from protons, illustrating
the significant reduction in normal tissue dose for an identical physical dose to the tumour.
Combining the results obtained here and the RBE estimate in (Holzscheiter et al 2006) of
around 2 (for a slightly spread-out annihilation peak), this imposes an even further decrease
of the biologically effective dose in the entrance region as compared to a proton beam with
identical biological effect in the target region.
11 Ionization chamber electrodes consist of carbon, and the plastic housing is expected to consist of a carbon-rich
compound too.
12 N Bassler et al
The comparison of proton and antiproton depth–doses at the same range shows the
immense potential of antiprotons to reduce the dose to normal tissue in the entrance region of
the particles, even without taking any increase in biological efficiency into account.
It should of course be mentioned that the dose beyond the Bragg peak is non-negligible
in the case of antiprotons, which is due to the annihilation products. This dose contribution,
however, is not a major concern for most clinical applications and both smaller in value and of
shorter range than the dose in the fragment tail of, e.g., carbon ions. Thus, the improvement
of the depth–dose characteristic of antiprotons as compared to protons seems to be undoubted.
The remaining open question to be answered is the lateral dose distribution from antiprotons,
especially close to the annihilation region. If the dose due to secondary particles is spread
out significantly more in the lateral direction as compared to protons, this may be a serious
drawback for the clinical use of antiprotons. Since the annihilation event happens at rest and
is therefore isotropic in its effect we can already deduce some information from the distal
edge of the Bragg peak. From our earlier measurements (Holzscheiter et al 2006) we expect
the penumbra of antiproton beams to be only slightly larger than for protons. In addition, the
effect of the diffuse and apparently weak dose from pions, gammas and neutrons on tissue far
from the target area needs to be considered.
We are currently investigating this topic with model calculations along with experiments
attempting to assess the peripheral dose, and this work will be the subject of a future publication
which is in preparation.
6. Conclusion
Simulations with FLUKA 2006.3 are in excellent agreement with our relative measurements.
In terms of absolute dose, our measurements are 6–9% higher than the FLUKA calculations, but
this may be attributed to uncertainties in the saturation correction, the Monte Carlo simulation,
the calibration of the ion chambers or a systematic shift in the number of antiprotons entering
the target.
SHIELD-HIT v.2.2 overestimated the peak–plateau ratio, which is most likely related to
the annihilation cross sections used by this code. Using ion chamber dosimetry, for the first
time an absolute value of the absorbed dose in a beam of antiprotons could be determined.
This enables a quantitative evaluation of the relative biological effectiveness of antiprotons and
proves the superiority of the depth–dose distribution of antiprotons as compared to protons.
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Abstract
In this paper we report on the measurement of the antiproton depth dose curve,
with alanine detectors. The results are compared with simulations using the par-
ticle energy spectrum calculated by FLUKA, and using the track structure model
of Hansen and Olsen for conversion of calculated dose into response. A good agree-
ment is observed between the measured and calculated relative effectiveness al-
though an underestimation of the measured values beyond the Bragg-peak remains
unexplained. The model prediction of response of alanine towards heavy charged
particles encourages future use of the alanine detectors for dosimetry of mixed ra-
diation fields.
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In radiotherapy of deep seated tumours it is advantageous to be able to deliver
the dose from ionizing radiation to the tumour while at the same time sparing
the surrounding normal tissue to maximum possible extend. The depth dose
profile of a proton beam is far superior to the depth dose beam of photons
in such cases, as the deposited energy peaks at the end of the range of the
primary charged particle track.
In 1984 Gray and Kalogeropoulos suggested radiotherapy with antiprotons [1].
One of the anticipated advantages of antiprotons compared to protons, is the
additional energy deposited at the Bragg-peak from the antiproton annihila-
tion. Sullivan suggested in [2] that the additional local energy deposited by the
annihilation products may roughly be about 30 MeV over the last 0.5 g cm−2
of its trajectory. Even though this value sounds low compared with the total
of 1.88 GeV released by the annihilation, this still results in a substantial aug-
mentation of the peak dose at the end of the particle track. Roughly, a proton
has about 20 MeV left of kinetic energy before the onset of the Bragg-peak
(corresponding to a residual range of 0.5 g cm−2) and the additional 30 MeV
would therefore more than double the energy deposited in the peak region.
In this paper we try to characterize the antiproton annihilation peak, using
alanine detectors.
To interpret a measured response of a biological system exposed to a beam
of charged particles in terms of dose deposition, a prediction of the Relative
Biological Effectiveness (RBE) for the particular beam of particles is necessary.
Similarly, for a radiation detector the relative effectiveness (RE) is relating the
observed detector response with dose deposition. The observed response of a
detector is here expressed in terms of the dose R, which is the dose as read
from the 60Co γ-ray response curve. This term will exclusively be used here
to express response. For the dose Dion deposited by ions and the secondary
particles produced along the primary beam path, we have
Rion = RE ·Dion (1)
Thus, Rion is the response of a detector exposed to ion beams, expressed in
terms of the dose by γ-rays necessary to produce an equal response. Here,
“ion” means any primary particle with Z ≥ 1. Note, that often the term
Heavy Charged Particles (HCPs) is used, referring to particles with Z > 1.
For a given biological system and chosen endpoint, RBE is a function of the
target parameters, atomic number and velocity of the bombarding particle.
This is why the RBE in the plateau region is different from that in the Bragg-



































































penetration, even though an increase of RBE beyond this value has been
observed for the distal edge of the Bragg-peak [3, 4].
For HCPs the increase of RBE with depth becomes more pronounced and also
shifts towards the entrance to the target with increasing atomic number. For
antiprotons compared to protons of the same energy, the RBE is anticipated
to be further enhanced in the peak region, due to the annihilation process
which yields fragments with Z > 1. In the plateau region, antiprotons are
expected to exhibit an RBE similar to that of protons.
The RE of a detector is expected to behave similar: in the peak region of the
depth-dose curve we expect a lower RE due to secondary particles which may
have a higher LET [5].
Attempts to measure the RBE of antiprotons directly in the peak region have
failed so far [6–8], since any RBE determination requires knowledge of the
dose. Dosimetry of the antiproton depth dose curve is problematic since all
applicable dosimeters known to us show non-linear effects in response when
being exposed to ion beams. This is true for e.g. silicon diodes [9, 10], diamond
detectors [10, 11], radiochromic films [12] and alanine [13].
At CERN the antiproton beam has a pulsed structure which leads to ionic
recombination effects in ionization chambers [14–17]. Measurements using
Boag’s theorem [18, 19] correcting for recombination effects have been per-
formed and are described in [20]. Calorimetry is the most direct way to measure
absorbed dose according to its definition. However, calorimeters are cumber-
some to use and are not easily applicable in a low-frequency pulsed beam such
as CERN’s antiproton beam. Other detectors we have applied in the antipro-
ton beam are lithium fluoride based thermoluminescent devices (TLDs) and
radiochromic films [21]. This paper, however, will concentrate on the results
achieved with alanine detectors.
L-α-alanine is an amino acid which occurs naturally in the human body. When
alanine is irradiated with ionizing radiation, it forms the stable radical CH3-
C˙H-COOH. Using an electron spin resonance (ESR) reader, the free electron
pair at the chiral carbon atom can be detected. The magnitude of the ESR
response depends on the amount of absorbed dose, and Bradshaw et al. [22]
first suggested to use this detector as a dosimeter. The behaviour of alanine in
photonic fields is well characterized [23]. The dynamic range of these pellets
is large, ranging from 0.5 Gy to 100 kGy, being linear in the region up to 10
kGy. Kudoh et al. [24] showed that there was no dose rate effect when exposing
2.34 kGy X-rays within 70 ns. The response of alanine detectors to HCPs was
investigated by Hansen and Olsen in the 80’s [25, 26]. A model explaining
the behaviour based upon the Butts and Katz track structure idea [27, 28]



































































alanine detectors, including fading effects - a phenomenon being of importance
in the evaluation of dose-response for alanine detectors exposed to beams of
HCPs: The temporal instability of the ESR signal in alanine after exposure to
ionizing radiation, has been reported to be rather insignificant at low doses,
but becoming more significant when approaching saturation doses of ∼ 5×105
Gy [25]. It was measured to be less than 1% per year for low-LET radiation,
but as much as 16% after 4000 hours when exposing alanine to high doses
(5× 105 Gy) of 16 MeV protons, and 22% for 106 Gy from stopping 21 MeV
7Li-ions [23]. At lower doses (but at the same dose rate), the decay of the ESR
signal from 104 Gy of 16 MeV protons stabilizes to 3% after 4000 hours. The
decay in alanine is dominant within the first 100 to 200 hours after exposure
to HCPs, and the rate of decay is different for pellets positioned in the plateau
compared to those in the Bragg-peak [30].
The difference in fading rate between high and low-LET radiation and high
and low dose is attributed to radical recombination effects in the microscopic
high dose regions of the particle tracks [30]. Fading predictions based on the
model of track structure have shown to conform to experimental data [26].
Concluding, due to the higher atomic number of annihilation fragments in the
Bragg-peak of antiprotons the fading processes will be more pronounced and
should from a theoretical point of view be taken into account when comparing
the radiation effect in the Bragg-peak with that of protons.
Here we shall apply the track structure model on a mixed particle energy
spectrum simulated by FLUKA, in order to calculate the RE and then the
expected response of alanine pellets based on the measured 60Co γ-ray dose-
response curve. The predicted response as a function of penetration depth is
compared to that measured from a stack of alanine pellets exposed to a beam
of antiprotons.
2 Experimental Methods
Two stacks of alanine pellets are irradiated with antiprotons. The pellets in
stack #1 consist of finely grained crystalline alanine powder (Merck) 95% by
weight mixed with 5% by weight polyvinyl-pyrrolidone (Polyvidone, Merck)
as the binding agent and are manufactured by J.W. Hansen. The pellets have
an outer diameter of 4.5 mm, an average thickness of 2 mm, and a density of
1.210 g cm−3. Details about the dosimeter pellets are published in [29]. In this
stack seven pellets are placed in the plateau, and 18 pellets are placed around
the annihilation peak and are surrounded by a polystyrene phantom.



































































of 90% by weight L-α-alanine and 10% high melting point paraffin wax. The
diameter of the pellets is 5 mm and the thickness is either 2.2 mm or 0.44 mm
(average values for the entire batch). The average density is 1.235 g cm−3. The
stack is assembled from eleven 2.2 mm pellets, six 0.44 mm pellets and five
2.2 mm pellets, arranged in a 5.2 mm cylindrical hole in a PMMA phantom.
We used a build-up plate of 81.8 mm polystyrene in order to position the
Bragg-peak around the position of the thin pellets.
The Antiproton Decelerator (AD) at CERN provides a 502 MeV/c (∼126
MeV) antiproton beam. Every 90 seconds a spill consisting of roughly 3 · 107
antiprotons is ejected within 300 ns. The momentum spread of the beam is
∆p/p = 5 · 10−4, and the divergence is in the order of 5 mrad. The beam exits
the accelerator vacuum via a thin titanium window and is collimated to 1 cm
diameter.
The absolute number of particles extracted from the AD is determined by a
fast current transformer mounted downstream of the extraction septum in the
beam line feeding our experimental set-up. Earlier studies show that this num-
ber possibly has a tendency to overestimate the amount of antiprotons hitting
the target by 10 - 20%. This may be due to calibration errors and/or to losses
in the final stretches of the beam line leading up to our set-up. In addition, for
stack #1 we could only randomly manual check the number of antiprotons per
spill, due to a temporary problem in the AD logging system. Those numbers
were used to derive the best estimate of the amount of antiprotons hitting the
alanine stack. The precision of this estimate is in the order of +/- 5 %. For
stack #2 the problems were solved, and every spill was logged.
We verify the alignment of the two stacks with two radiochromic films (GAFChromic
HS and EBT) which are inserted along the beam. The FWHM of the beam
when irradiating stack #2 is almost circular with a FWHM of 0.9 and 1.0
cm along the x and y axis. The beam which is used for stack #1 has a more
ellipsoid form of about 0.6 - 1.0 cm FWHM along the x and y axis, respec-
tively. The ESR signal of the pellets in stack #1 is read out by the Radiation
Research Department at the Risø, National Laboratory in Denmark, using a
Bruker EMS 104 EPR alanine readout device. Stack #1 is read out several
times at increasing time intervals, in order to detect any fading effects, as re-
ported in [30]. At each readout, the pellet is measured at zero and 90◦ rotation
and a mean signal strength is obtained. Stack #2 is read out at the National
Physics Laboratory (NPL) in the UK using the standard procedures for NPL’s
radiotherapy level alanine dosimetry service [31]. The spectrometer is a Bruker
ESX and a standard Bruker ST4102 rectangular cavity. The acquisition time
is 120 s consisting of six 20 s scans with 90◦ rotation of the pellet between the
third and fourth scan. The pellets are introduced in the spectrometer using
an automated loading system with a specially constructed sample holder to




































































FLUKA [33, 34] version 2006.3 is used for calculating the antiproton particle
transport through the medium and the distribution of secondaries in each
alanine pellet. The geometry of both stacks is carefully implemented, including
correct densities and chemical compositions of target and phantom materials.
The beam profiles measured with the radiochromic films is used as an input
parameter for FLUKA for stack #1 and stack #2. We find for stack #1 a
little misalignment of 2 mm and a rotation of the phantom of a half degree,
which we include in the FLUKA calculations. 500.000 particles are used for the
statistics, using the FLUKA hadron therapy “HADROTHE” default settings.
The dose D for all particles (including contribution from γ-rays) is scored in
every pellet position using the “USRBIN” card in FLUKA. A custom user
routine is written to determine the dose Dγ from electromagnetic transport
(γ-rays, electrons, positions) and DR. DR is a dose derived from what FLUKA
defines as “kerma energy”, which is energy being transferred to particles which
are not transported further and again deposit their energy at the production
point. These particles are not further identified in FLUKA, but it is expected
to be related to low-energy neutron reactions and possibly also low-energy
heavy recoils from the annihilation process.
In addition, we record the track length fluence-energy spectrum φ[Ej, Zi] for
pions, kaons and all nuclei with 1 ≤ Z ≤ 6 for each pellet using the “USR-
TRACK” card in FLUKA. Another user routine is written in order to group
all particles of equal charge. For example Z = 1 covers all pions (pi+, pi−,
pi0), kaons (K+, K−, K0S, K
0
L, K
0, K¯0), antiprotons, protons, deuterons and
tritons. Higher charges Z ≥ 2 includes all isotopes of the respective charge.
The energy binning is done in energy per nucleon, which eases further data
processing by using the fact that particles with equal charge and equal en-
ergy per nucleon have equal stopping power. For instance, pions are therefore
treated as protons with mass A = 0.15 amu. The energy range scored ranges
from 10 keV/nucleon to 1 GeV/nucleon in 100 logarithmic steps. We neglect
effects of changing the charge sign, since the Barkas effect [35] is insignificant
for our calculations. Thus, in all calculations antiprotons have equal stopping
power as protons.
From FLUKA we can build a fluence matrix φ[Ej , Zi] which is divided in
particle types Zi and energy bins with the mean energy per nucleon Ej .
For the relative efficiency calculations, the same approach of grouping the
particles in terms of charge and energy per nucleon is taken, since the default
model is not capable of treating pions, antiprotons or kaons.



















































































(Ej, Zi) is the mass stopping power for particle Zi at energy Ej . The
stopping power is evaluated at the center of the energy bin using the PSTAR
and ASTAR routines by Berger et al. [36] for Z = 1 and Z = 2 respectively,
and MSTAR (by Paul and Shinner [37, 38]) is used for Z > 2. Since we use
track length dose, the energy dissipation of primary and secondary particles,
when passing through the pellet of interest, is accounted for, when calculating
DTL.
The dose DTL calculated by the track length fluence, is lower than the FLUKA
dose D, since photons and low energy recoils are not included in the DTL
calculation. Instead these contributions are scored directly in Dγ and DR as
mentioned before. The contribution from Dγ and DR to the total dose is about
1-2 % in the plateau region and about 7-9 % in the pellet(s) covering the peak
region. The total summed dose DTOTAL is therefore
DTOTAL = DTL +Dγ +DR (3)
DTOTAL still differs from the direct way of calculating the dose D due to
rounding errors from the binning, and perhaps even due to the use of external
stopping power tables, which may differ from what FLUKA internally uses.
The difference is 4% in the peak and 1% in the plateau.
From the track length fluence matrix φ[Ej , Zi] the relative effectiveness of each
particle-energy entry is looked up in a table. This RE table is generated using
the model by Hansen and Olsen for infinitesimal thin detectors and the results
are shown in figure 1.
By summing all individual detector responses Rion(Ej, Zi) = RE(Ej , Zi)D(Ej , Zi)
for each energy bin Ej and particle type Zi, we find a total dose weighted aver-
















where REγ and RER is the relative efficiency for the electromagnetic transport



























































































Fig. 1. Calculated relative efficiencies for infinitesimal thin detectors, without fading
effects.
FLUKA does not return the exact composition of the low-energy recoils, we
cannot calculate RER. Figure 1 indicates that this part the RE may lie between
0.0 and 0.2 for HCPs. since these particles are expected to have energies below
100 keV, which is the default cut-off energy for hadron transport. The Hansen
and Olsen model suggest fading effects ranging from 9% to 87% for a 12C nuclei
with 10 keV/nucleon and 100 keV/nucleon, respectively, after 1900 hours of
fading. As an estimate we set RER to be = 0.1 with fading, and without fading
we set RER = 0.2.
At last, we multiply the calculated RE with the total dose D (representing
the exact dose) scored by FLUKA for each pellet. This gives the response Rion
expressed in equivalent γ-ray dose:
Rion(D) = RE ·D (6)
4 Results
In figures 2 and 3 the total measured response of the alanine pellets as a
function of penetration depth is plotted together with the response calculations
and the predicted dose for stack #1 and #2, respectively. Fading effects are
included in these calculations. The response is expressed in terms of response
equivalent gamma dose.



































































is measured upstream of the target with the beam current transformer. This
possibly introduces a systematic error in dose, since fractions of the beam
may be lost on the way from the transformer to the experimental setup, as
mentioned earlier.
For stack #1 in figure 2 the measured peak was found 1.5 mm further down-
stream compared to the calculations. Therefore the measurements have been
shifted 1.5 mm upstream the beam axis, in order to match the peaks. Inves-
tigation of the fading of the alanine tablets is attempted with alanine stack
#1. Unfortunately the ESR-spectrometer for these readings turned out to be
rather unstable resulting in unreliable measurements for which fading could
not be determined with a sufficient accuracy. This error in precision is re-
flected by the 1 σ standard deviation error bars in figure 2. From calculated
predictions we expect to find a difference of less than 1% in fading between
dosimeters positioned at the plateau and in the peak (see also figure 4). There-
fore the expected fading is too small to be observable. Most of this fading in
response is considered to take place within 200 hours after irradiation. Here
we apply 1900 hours of fading for both stacks. As we mentioned earlier it is
difficult to asses the amount of fading for RER, since the exact composition is
not known.
0 2 4 6 8 10 12












FLUKA Dose * RE
Measurements
Fig. 2. Stack #1 results. The thin (black) line shows the dose for each pellet as
it is calculated by FLUKA. The calculated dose multiplied with the calculated
relative effectiveness is plotted as a thick (red) line, and should ideally match the
measurements marked as unconnected squares. Measured response is translated to
dose using the γ-ray dose-response curve. The measurements are shifted 1.5 mm
upstream in order to match the results.

















































































FLUKA Dose * RE
Measurements
Fig. 3. Results for stack #2 plotted in the same fashion as figure 2. No shift along
the x-axis needed to be applied here.












Including 1900 hours fading
Fig. 4. Calculated relative effectiveness for stack #2 as a function of depth in phan-
tom. The relative effectiveness drops off in the peak region due to the slowing down
of antiprotons and the annihilation products with higher LET. The calculation is
done twice, including and excluding fading effects.
5 Discussion
One of the major differences between stack #1 and #2, is the fitting of the
pellet diameter to the 5 mm hole drilled into the phantom. Stack #1 leaves
a gap in between the pellet and the cavity wall whereas the stack #2 pellets fit
the hole exactly. The presence of this gap enables some antiprotons to tunnel



































































cylindrical form, but had a little edge at the rim of the outer diameter. These
effects are not included in the FLUKA simulations, since this is difficult to
quantify. The result is that some antiprotons have a larger observed range,
which in turn widens the peak, and localizes it further downstream the beam
axis. This may possibly explain the shift of 1.5 mm downstream from the
predicted position of the measured peak. This effect is thought to be much
less pronounced for stack #2, as these pellets have perfect cylindrical form
which closely matches the phantom cavity.
Another difference between both stacks is the density matching of the pellets
and the surrounding phantom. For stack #1 the alanine pellets had 1.21 g
cm−3 and are surrounded by polystyrene with 1.04 g cm−3. For stack #2 the
1.235 g cm−3 pellets are surrounded by a PMMA phantom with a density of
1.19 g cm−3. This is accounted for in the FLUKA calculations and causes the
difference in the shape of the tail since antiprotons can penetrate deeper in
the surrounding phantom as in the alanine stack and their annihilation can
contribute to dose beyond the Bragg-peak.
The RE is fairly close to unity in the plateau region, and drops down to about
0.75 in the peak region. Compared to the RE of e.g. low energy carbon ions
(see figure 1) the change in RE for antiprotons is rather small. The reason
for this rather slight change in RE is due to the low atomic number of the
antiproton itself but also due to the resulting mixed field of relatively light
nuclei from the antiproton annihilation as described by Polster et al. [39].
Other detectors such as TLDs show a significantly higher loss of RE for light
nuclei with low energy, see e.g. [40, 41].
Both stacks provide absolute dose measurements. Since the plateau region of
the stack #2 fits the calculations very well, the systematic effect of a possible
overestimate of the recorded particle fluence due to the upstream position of
the beam current transformer seems to be minor. Absolute dose measurements
for stack #1 are more problematic, since the alanine readout device had a
tendency to drift as mentioned earlier.
Due to the volume averaging effects, we focus on the stack #2. Here we see a
6% underestimation of the calculated dose in the plateau region. The agree-
ment of the calculated dose in the annihilation peak is better than 3%, but in
the tail the underestimation is almost ∼40%. The nature of this underestima-
tion is not clear, and several possible explanations exist:
• unknown accuracy of the beam current monitor
• incorrect representation of the geometry used as input parameter for the
FLUKA calculations




































































• limitation of the inherent model in the FLUKA code to predict the annihi-
lation peak accurately
On the experimental side a source of error may be the fact that the pellets
consists of grains in a matrix whereas the Monte Carlo simulations assume a
homogeneous mixture. Finally, the local shape of the annihilation peak is very
sensitive to volume averaging effects, which may not be reproduced accurately
in the Monte Carlo simulation.
Furthermore it should be noted that alanine together with model calculations
of RE is a promising dosimeter in mixed radiation fields as formerly shown for
neutrons [42]. In a real clinical situation, one would never use a pristine beam,
but a spread out beam covering a larger treatment volume. This dilutes the
RE further as the Bragg-peak is mixed with the field from primary particles
and reduces the error of dosimetry in the spread out peak region further.
Models based on track structure theory by Butts and Katz [27], and deriva-
tives of the Local Effect Model [43–45] such as ECLaT [46] for TLDs, rely
on predicting the response of a detector from the γ-response curve which is
convoluted with the radial dose distribution of a track in order to achieve the
relative effectiveness of the HCP radiation in question. Here we would like to
speculate on the link between track interactions and saturation level of the
γ-response curve. In mixed radiation fields, the track structure model and the
local effect model use different approaches in calculating track interaction ef-
fects, an overview of these differences is given in [47]. In this paper though,
the response calculations are further simplified since interactions between two
or multiple tracks are not considered. Track interactions are most likely to
happen at high fluences where the mean track distance
√
φ−1 becomes similar
to that part of the track radius in which ”cross-overs” would lead to satura-
tion response. For a clinical setting with a fluence of 109 cm−2 (per fraction)
the mean track distance would be 3 · 10−5 cm. One can estimate a significant
track-radius from the amorphous radial dose distribution of a track, where
saturation effects occur. This radius is depending on particle energy and par-
ticle charge, but it will decrease, the higher the onset of saturation is on the
γ-response curve. If we assume 10 kGy as the onset of saturation effects for
alanine, this would give a radius in the order of 10−6 cm for an oxygen ion with
3 MeV [30]. This radius will decrease further for decreasing charge. Neglecting
of track interactions in the calculation of effectiveness should be possible due
to the high saturation dose of alanine.
The region of saturation in a single particle track is smaller in a detector with
a high saturation level, i.e. low radiation sensitivity, than that of a detector
with a low saturation level, i.e. high radiation sensitivity. Therefore the effect




































































In this paper we have described the use of alanine detectors for the dosimetry
of the mixed particle field arising from antiproton annihilation. The results
could be reproduced using the relative effectiveness calculated with the track
structure model by Hansen and Olsen used in conjunction with doses and par-
ticle spectra calculated with FLUKA. Forward calculation using this method
shows that dose verification is possible, and in principle medical dosimetry
can be reconstructed from the alanine response. We conclude that the alanine
detector is an interesting detector for characterizing the mixed radiation field
from antiproton annihilation. This detector could also be applied for dosime-
try of medical heavy ion beams and possibly in mixed radiation fields found
in space. NPL alanine dosimetry service can measure the dose from 5 Gy up-
wards with a precision of 1% (1 σ). This is well within the dose levels used in
radiotherapy. Even if ESR spectrometers are not widespread in clinical envi-
ronments and readout may be time-consuming, this dosimeter has still some
advantages: it is easy to handle, the read-out is non-destructive, and alanine
has a tissue-equivalent composition.
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